Literature DB >> 9041856

Response of the pupil to tropicamide is not a reliable test for Alzheimer disease.

J S FitzSimon1, S C Waring, E Kokmen, J W McLaren, R F Brubaker.   

Abstract

OBJECTIVE: To confirm the putative hypersensitivity of the pupil to a weak mydriatic in persons with Alzheimer dementia.
DESIGN: Twenty patients with Alzheimer dementia and 20 control subjects were examined. Automated binocular infrared pupillography was performed in the dark after instillation of 0.01% tropicamide or placebo. Ocular penetration of eye drops was assessed simultaneously using 2% fluorescein sodium as a tracer.
SETTING: Rochester, Minn.
SUBJECTS: Twenty patients and 20 cognitively normal control subjects from the Alzheimer's Disease Patient Registry of the Mayo Clinic, Rochester, Minn. MAIN OUTCOME MEASURE: Percent change in the diameter of the pupil following topical ocular instillation of a diluted concentration of the mydriatic drug tropicamide and penetration of topically applied fluorescein into the aqueous humor.
RESULTS: No statistically significant difference was found between patients with Alzheimer disease and control subjects in either the mydriatic response of the pupil or in the rate of penetration of topically applied fluorescein.
CONCLUSION: No evidence of pupillary hypersensitivity to an anticholinergic mydriatic drug was found in patients with Alzheimer disease or any evidence that this putative hypersensitivity could be used as an early, simple diagnostic test for Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9041856     DOI: 10.1001/archneur.1997.00550140031009

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  2 in total

1.  Why patients with Alzheimer's disease may show increased sensitivity to tropicamide eye drops: role of locus coeruleus.

Authors:  R H Hou; E R Samuels; M Raisi; R W Langley; E Szabadi; C M Bradshaw
Journal:  Psychopharmacology (Berl)       Date:  2005-11-25       Impact factor: 4.530

2.  Pupil response biomarkers distinguish amyloid precursor protein mutation carriers from non-carriers.

Authors:  Shaun M Frost; Yogesan Kanagasingam; Hamid R Sohrabi; Kevin Taddei; Randall Bateman; John Morris; Tammie Benzinger; Alison Goate; Colin L Masters; Ralph N Martins
Journal:  Curr Alzheimer Res       Date:  2013-10       Impact factor: 3.498

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.